Alsina, MariaRivera, FernandoRamos, Francisco JavierGalan, MaicaLopez, RafaelGarcia-Alfonso, PilarAles-Martinez, Jose EnriqueQueralt, BernardoAnton, AntonioCarrato, AlfredoGravalos, CristinaMendez-Vidal, Maria JoseLopez, Carlosde Mena, Inmaculada RuizTabernero, JosepGiralt, JordiAranda, Enrique2023-01-252023-01-252018Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, et al. Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol. 2018 Feb;13(1):79http://hdl.handle.net/10668/11911Background: Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional oesophageal cancer patients, despite a non-negligible failure rate. Objective: We evaluated intensification of this approach to improve patient outcomes by adding cetuximab to induction 5-FU/cisplatin/docetaxel (TPF) and to chemoradiotherapy in a phase II study. Patients and methods: Between November 2006 and April 2009, 50 patients with stage II-IVa squamous cell carcinoma (SCC) or adenocarcinoma of the oesophagus or gastro-oesophageal junction initiated three TPF/cetuximab cycles. Six weeks later, patients with response or stabilisation initiated 6 weeks of cisplatin/cetuximab/radiotherapy, followed by surgery. The primary objective was the clinical complete response (cCR) rate after induction therapy plus chemoradiotherapy in intent-to-treat patients. Results: Thirty-eight patients were evaluable after chemoradiotherapy, 84% of whom showed disease control. Six patients (12%) achieved a cCR, with a 54% overall response rate. Twenty-seven patients underwent surgery, 11 of whom (22%; nine SCC, two adenocarcinoma) had a pathological CR (41%). Fifteen patients were alive after a median follow-up of 23.2 months. Median progression-free survival was 12.2 months (95% confidence interval [CI] 1.7-22.8). Median overall survival was 23.4 months (95% CI 12.2-36.6) and was significantly longer among the 22 patients with complete resection than in the five patients without (42.1 vs. 24.9 months; p = 0.02, hazard ratio: 3.6, 95% CI 1.1-11.6). The toxicity profile was acceptable. Conclusions: Neoadjuvant cetuximab/TPF followed by chemoradiotherapy in locoregional oesophageal carcinoma patients is feasible and offers a modest response rate in this trial. The results of combining trimodality neoadjuvant treatment with cetuximab are consistent with the literature.enAdultAgedCetuximab / pharmacologyCetuximab / therapeutic use*Chemoradiotherapy / methods*Esophageal neoplasmsFemaleHumansMaleMiddle agedresearch article29243205open accessNeoplasias esofágicasPersona de mediana edadQuimioradioterapia10.1007/s11523-017-0544-z1776-260Xhttps://link.springer.com/content/pdf/10.1007/s11523-017-0544-z.pdf